Director Shareholding
30 May 2003 - 1:16AM
UK Regulatory
RNS Number:6945L
Cambridge Antibody Tech Group PLC
29 May 2003
SCHEDULE 11
NOTIFICATION OF INTERESTS OF DIRECTORS AND CONNECTED PERSONS
1) Name of company
Cambridge Antibody Technology
2) Name of director
Peter Chambre
3) Please state whether notification indicates that it is in respect of
holding of the shareholder named in 2 above or in respect of a
non-beneficial interest or in the case of an individual holder if it is a
holding of that person's spouse or children under the age of 18 or in respect of
a non-beneficial interest
As in 2 above
4) Name of the registered holder(s) and, if more than one holder, the
number of shares held by each of them (if notified)
As in 2 above
5) Please state whether notification relates to a person(s) connected
with the Director named in 2 above and identify the connected person(s)
As in 2 above
6) Please state the nature of the transaction. For PEP transactions
please indicate whether general/single co PEP and if discretionary/non
discretionary
Grant of options under Company Share Option Plan
7) Number of shares/amount of
stock acquired
8) Percentage of issued class
9) Number of shares/amount
of stock disposed
10) Percentage of issued class
11) Class of security
12) Price per share
13) Date of transaction
14) Date company informed
15) Total holding following this notification
16) Total percentage holding of issued class following this notification
If a director has been granted options by the company please complete the
following boxes
17) Date of grant
23 May 2003. Notification delayed due to an administrative error.
18) Period during which or date on which exercisable
23 May 2006 - 22 May 2013 subject to performance conditions
19) Total amount paid (if any) for grant of the option
Nil
20) Description of shares or debentures involved: class, number
Ordinary 10p shares - 146,956
21) Exercise price (if fixed at time of grant) or indication that price
is to be fixed at time of exercise
#4.60
22) Total number of shares or debentures over which options held
following this notification
206,974
23) Any additional information
All of the 146,956 options granted will only become exercisable subject to the
satisfaction of a performance condition and of that number 36,739 options will
only become exercisable subject to the satisfaction of an additional stringent
performance condition.
24) Name of contact and telephone number for queries
Diane Mellett 01223 471471
25) Name and signature of authorised company official responsible for
making this notification
Diane Mellett Company Secretary
Date of Notification 29 May 2003
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSEASSNAFSDEFE